CagriSema (Cagrilintide + Semaglutide)

CagriSema lands at Neutral because it pairs the strongest weight effect in this incretin batch with the weakest set of supporting facts around it. The potency is real: about 22.7% loss on-treatment, a novel amylin plus GLP-1 mechanism, and two solid Phase 3 trials, per Garvey 2025. But it is not approved anywhere, it lost a head-to-head to tirzepatide, it carries the heaviest gastrointestinal load of the batch, and there is no heart-outcomes data. For anyone needing treatment today, the approved and slightly stronger option already exists. CagriSema is worth watching closely, not chasing through gray-market channels.

✅ Best for: People researching the obesity-drug pipeline who want to understand the strongest dual-mechanism injectable on the horizon. Those who specifically want the amylin plus GLP-1 route rather than the GIP-based path, perhaps after a poor response to GIP-based drugs, though that benefit is unproven. Patients with type 2 diabetes interested in a drug that drove 74% to an HbA1c at or below 6.5% in trials, per Kahn 2025. People willing to wait for the expected FDA approval in late 2026 rather than source an unapproved drug. Anyone who can tolerate a slow 16-week ramp and a high early gastrointestinal load.

❌ Avoid if: You have a personal or family history of medullary thyroid carcinoma or MEN 2, since the class carries a thyroid C-cell warning, per Kahn 2025. You have had pancreatitis, active gallbladder disease, or severe gastrointestinal disease. You are pregnant or breastfeeding, with no safety data. You take insulin or sulfonylureas without medical supervision, since hypoglycemia risk rises. You need a treatment now, since CagriSema is not legally available and an approved, slightly stronger option exists. You cannot verify source quality, because every current channel is gray-market with real identity and purity risks.